2.490USD-30.83%Mkt Cap: 122.61M USDP/E: —Last update: 2026-05-26
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the Un…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap122.61M USD
Enterprise Value183.45M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.98M USD
Revenue/Share—
Last Price2.490 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B41.04
EPS (TTM)-0.14
EPS (Forward)—
52W Range
2.2001% of range48.91
52W High48.91 USD
52W Low2.200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-196.82%
ROA-173.79%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.94M USD
CapEx (TTM)—
FCF Margin—
FCF Yield2.00%
Net Debt-3.08M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio3.45
Quick Ratio3.04
Book Value/Sh0.0960 USD
Cash/Share0.0650 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)10.00 USD
Target Range10.00 USD – 10.00 USD
# Analysts1
Ownership
Shares Out.47.34M
Float4.98M
Insiders73.01%
Institutions8.31%
Short Interest
Short Ratio1.3d
Short % Float1.40%
Short % Out.0.56%
Shares Short266.65K
Short (prev mo.)393.31K
Technical
SMA 505.259 (-52.7%)
SMA 2005.742 (-56.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)230.21K
Avg Vol (10d)288.61K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—